Skip to main content
. 2018 Nov 13;18(4):271–282. doi: 10.1007/s40268-018-0254-8

Fig. 2.

Fig. 2

A comparison of the proportion of any recorded GI-related adverse effect for MMF and EC-MPS. Bar A corresponds with the results from Langone et al. [39]; bars B, C and D correspond with the results from Budde et al. [18]; bar E corresponds with results from Salvadori et al. [19]. Direct comparisons for each analogous pair were not significant in all cases. EC-MPS enteric-coated mycophenolate sodium, GI gastrointestinal, MMF mycophenolate mofetil